Abstract

This meta-analysis examined the efficacy of different dosing regimens containing rituximab (RTX) in treating pemphigus. The analysis included 578 patients with pemphigus from 30 studies. Seventy-six percent of patients achieved complete remission after one cycle of RTX. Mean time to remission was 5.8 months, with a remission duration of 14.5 months and a 40% relapse rate. Eighteen patients (3.3%) developed serious adverse effects. The pooled estimate showed no significant differences in complete remission and relapse rates between patients treated with high-dose (near or ≥ 2,000 mg/cycle) vs. low-dose (<1,500 mg/cycle) RTX. In the fully adjusted analysis, high-dose RTX was associated with longer duration of complete remission compared with low-dose RTX. No superiority of lymphoma protocol over rheumatoid arthritis or high-dose RTX over lowdose RTX was shown in other outcomes. RTX treatment is efficacious and well-tolerated in treating pemphigus. High-dose RTX treatment may lead to longer duration of remission. However, the choice of optimal regimen depends on the overall condition of the individual patient.

Original languageEnglish
Pages (from-to)928-932
Number of pages5
JournalActa Dermato-Venereologica
Volume95
Issue number8
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

Pemphigus
Meta-Analysis
Rituximab
Recurrence
Lymphoma
Rheumatoid Arthritis

Keywords

  • Immunoadsorption
  • Lymphoma protocol
  • Pemphigus
  • Rheumatoid arthritis protocol
  • Rituximab

ASJC Scopus subject areas

  • Dermatology

Cite this

Efficacy of rituximab for pemphigus : A systematic review and meta-analysis of different regimens. / Wang, Hsiao Han; Liu, Che Wei; Li, Yu Chuan; Huang, Yu-Chen.

In: Acta Dermato-Venereologica, Vol. 95, No. 8, 01.11.2015, p. 928-932.

Research output: Contribution to journalArticle

@article{675c39510c334a908b90bb0da5c4cceb,
title = "Efficacy of rituximab for pemphigus: A systematic review and meta-analysis of different regimens",
abstract = "This meta-analysis examined the efficacy of different dosing regimens containing rituximab (RTX) in treating pemphigus. The analysis included 578 patients with pemphigus from 30 studies. Seventy-six percent of patients achieved complete remission after one cycle of RTX. Mean time to remission was 5.8 months, with a remission duration of 14.5 months and a 40{\%} relapse rate. Eighteen patients (3.3{\%}) developed serious adverse effects. The pooled estimate showed no significant differences in complete remission and relapse rates between patients treated with high-dose (near or ≥ 2,000 mg/cycle) vs. low-dose (<1,500 mg/cycle) RTX. In the fully adjusted analysis, high-dose RTX was associated with longer duration of complete remission compared with low-dose RTX. No superiority of lymphoma protocol over rheumatoid arthritis or high-dose RTX over lowdose RTX was shown in other outcomes. RTX treatment is efficacious and well-tolerated in treating pemphigus. High-dose RTX treatment may lead to longer duration of remission. However, the choice of optimal regimen depends on the overall condition of the individual patient.",
keywords = "Immunoadsorption, Lymphoma protocol, Pemphigus, Rheumatoid arthritis protocol, Rituximab",
author = "Wang, {Hsiao Han} and Liu, {Che Wei} and Li, {Yu Chuan} and Yu-Chen Huang",
year = "2015",
month = "11",
day = "1",
doi = "10.2340/00015555-2116",
language = "English",
volume = "95",
pages = "928--932",
journal = "Acta Dermato-Venereologica",
issn = "0001-5555",
publisher = "Society for the Publication of Acta Dermato-Venereologica",
number = "8",

}

TY - JOUR

T1 - Efficacy of rituximab for pemphigus

T2 - A systematic review and meta-analysis of different regimens

AU - Wang, Hsiao Han

AU - Liu, Che Wei

AU - Li, Yu Chuan

AU - Huang, Yu-Chen

PY - 2015/11/1

Y1 - 2015/11/1

N2 - This meta-analysis examined the efficacy of different dosing regimens containing rituximab (RTX) in treating pemphigus. The analysis included 578 patients with pemphigus from 30 studies. Seventy-six percent of patients achieved complete remission after one cycle of RTX. Mean time to remission was 5.8 months, with a remission duration of 14.5 months and a 40% relapse rate. Eighteen patients (3.3%) developed serious adverse effects. The pooled estimate showed no significant differences in complete remission and relapse rates between patients treated with high-dose (near or ≥ 2,000 mg/cycle) vs. low-dose (<1,500 mg/cycle) RTX. In the fully adjusted analysis, high-dose RTX was associated with longer duration of complete remission compared with low-dose RTX. No superiority of lymphoma protocol over rheumatoid arthritis or high-dose RTX over lowdose RTX was shown in other outcomes. RTX treatment is efficacious and well-tolerated in treating pemphigus. High-dose RTX treatment may lead to longer duration of remission. However, the choice of optimal regimen depends on the overall condition of the individual patient.

AB - This meta-analysis examined the efficacy of different dosing regimens containing rituximab (RTX) in treating pemphigus. The analysis included 578 patients with pemphigus from 30 studies. Seventy-six percent of patients achieved complete remission after one cycle of RTX. Mean time to remission was 5.8 months, with a remission duration of 14.5 months and a 40% relapse rate. Eighteen patients (3.3%) developed serious adverse effects. The pooled estimate showed no significant differences in complete remission and relapse rates between patients treated with high-dose (near or ≥ 2,000 mg/cycle) vs. low-dose (<1,500 mg/cycle) RTX. In the fully adjusted analysis, high-dose RTX was associated with longer duration of complete remission compared with low-dose RTX. No superiority of lymphoma protocol over rheumatoid arthritis or high-dose RTX over lowdose RTX was shown in other outcomes. RTX treatment is efficacious and well-tolerated in treating pemphigus. High-dose RTX treatment may lead to longer duration of remission. However, the choice of optimal regimen depends on the overall condition of the individual patient.

KW - Immunoadsorption

KW - Lymphoma protocol

KW - Pemphigus

KW - Rheumatoid arthritis protocol

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84944738854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944738854&partnerID=8YFLogxK

U2 - 10.2340/00015555-2116

DO - 10.2340/00015555-2116

M3 - Article

C2 - 25881672

AN - SCOPUS:84944738854

VL - 95

SP - 928

EP - 932

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

IS - 8

ER -